ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation

@inproceedings{Khatri2019ABLKI,
  title={ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation},
  author={Aaditya Khatri and Jing Jin Gu and Courtney M. McKernan and Xia Xu and Ann Marie Pendergast},
  booktitle={Oncotarget},
  year={2019}
}
Lung cancer is the leading cause of cancer mortality in the United States, with an overall five-year survival rate of ~16%. Non-small cell lung cancer (NSCLC) accounts for ~80% of all lung cancer cases, and the majority (40%) of these are adenocarcinomas. Loss of function point mutations in TP53 (46%) and activating mutations in KRAS (33%) are the most common mutations in human lung adenocarcinomas. Because neither of these genetic alterations are clinically actionable, chemotherapy remains the… CONTINUE READING
2
Twitter Mentions

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2018
VIEW 1 EXCERPT